In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?
HER2 Year in Review
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.
Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.
Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.
A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.
This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.
A novel cancer vaccine targeting HER2-positive malignancies has progressed quickly from mouse trials into early-phase human trials, with promising results.
A laboratory study found that combining anti-HER2 TKIs with trastuzumab and pertuzumab can result in enhanced anticancer activity in HER2+ breast cancer cell lines.
An update to guidelines from ASCO on the optimal management of patients with HER2+ breast cancer offers recommendations on timing and sequence of therapies.
Direct measurements of TRBV genes could provide a biomarker to predict response to dual HER2 blockade in women with HER2-positive breast cancer.